This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Journal of Hematology & Oncology Open Access 27 July 2023
-
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
BMC Pulmonary Medicine Open Access 09 January 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Farber HW, Loscalzo J . Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655–1665.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245.
Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A . Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801–808.
Garcia-Manero G, Schuster SJ, Patrick H, Martinez J . Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999; 60: 130–135.
Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007.
Massa M, Rosti V, Ramajoli I, Campanelli R, Pecci A, Viarengo G et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688–5695.
Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N et al. Hybrid cell–gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003; 108: 889–895.
Del Papa N, Colombo G, Fracchiolla N, Moronetti LM, Ingegnoli F, Maglione W et al. Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis. Arthritis Rheum 2004; 50: 1296–1304.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cortelezzi, A., Gritti, G., Del Papa, N. et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 22, 646–649 (2008). https://doi.org/10.1038/sj.leu.2404943
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404943
This article is cited by
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Journal of Hematology & Oncology (2023)
-
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease
International Journal of Hematology (2023)
-
Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
BMC Pulmonary Medicine (2020)
-
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis
Bone Marrow Transplantation (2020)
-
Prevalence of pulmonary hypertension in myelofibrosis
Annals of Hematology (2020)